Varenicline for smoking cessation in people with schizophrenia: A double blind randomized pilot study

Schizophrenia Research

Volumn 129, Issue 1, 2011, Pages 94-95

  Weiner, Elaine ^a   Buchholz, Alison ^a   Coffay, Agnes ^a   Liu, Fang ^a   McMahon, Robert P ^a   Buchanan, Robert W ^a   Kelly, Deanna L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; PLACEBO; VARENICLINE;

ANXIETY; BRIEF PSYCHIATRIC RATING SCALE; CALGARY DEPRESSION SCALE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUNSELING; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INSOMNIA; LETTER; NAUSEA; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT; SMOKING CESSATION;

ADULT; BENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NICOTINIC AGONISTS; PILOT PROJECTS; QUINOXALINES; SCHIZOPHRENIA; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 79956066309     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.02.003     Document Type: Letter

References (12)

1. Anghelescu I. Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. J. Neuropsychiatry Clin. Neurosci. 2009, 21(1):102-103. Winter.
2. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 2008, 16(3):CD006103. Jul.
3. Evins A.E., Goff D.C. Varenicline treatment for smokers with schizophrenia: a case series. J. Clin. Psychiatry 2008, 69(6):1016. Jun.
4. Fatemi S.H. Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr. Res. 2008, 103(1-3):328-329. Aug Epub 2008 Jun 24.
5. Freedman R. Exacerbation of schizophrenia by varenicline. Am. J. Psychiatry 2007, 164(8):1269. Aug.
6. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br. J. Addict. 1991, 86:1119-1127. 18.
7. Henningfield J.E., Stitzer M.L., Griffiths R.R. Expired air carbon monoxide accumulation and elimination as a function of number of cigarettes smoked. Addict. Behav. 1980, 5:265-272.
8. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10:799-812.
9. Popkin M.K. Exacerbation of recurrent depression as a result of treatment with varenicline. Am. J. Psychiatry 2008, 165(6):774. Jun.
10. Smith R.C., Lindenmayer J.P., Davis J.M., Cornwell J., Noth K., Gupta S., Sershen H., Lajtha A. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr. Res. 2009, 110(1-3):149-155. May Epub 2009 Feb 28.
11. Stapleton J.A., Watson L., Spirling L.I., Smith R., Milbrandt A., Ratcliffe M., Sutherland G. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008, 103(1):146-154. Jan Epub 2007 Nov 19.
12. U.S.Food and Drug Administration Public Health Advisory: Important Information on Chantix (varenicline). U S Food and Drug Administration, Center for Drug Evaluation and Research 2008, Accessed May 4, 2008, February 1. http://www.fda.gov/cder/drug/advisory/varenicline.htm.